CANCER DISCOVERY

CONTENTS

JUNE 2012 ■ VOLUME 2 ■ NUMBER 6













For more News and Research Watch, visit *Cancer Discovery* online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- Nanoparticles Could Pinpoint Brain Tumors
- Modified T Cells Survive Over Decade
- Gene Expression Signature Predicts Lung Cancer Relapse
- Assay Could Identify Indolent Prostate Cancers



ON THE COVER Martins and colleagues determined the order of *BRCA1* LOH, PTEN loss, and *TP53* mutation in single cells from breast tumors with germline *BRCA1* mutations. Surprisingly, *BRCA1* LOH was rarely the initiating event, and wild-type BRCA1 expression was not lost in every cell within a tumor. Instead, PTEN loss occurred first in the majority of cases, particularly in basal-like tumors, and *TP53* mutation was the initiating event in most luminal tumors. These findings provide insight into the evolution of *BRCA1*-mutant breast cancers and suggest that *BRCA1* loss is not a rate-limiting step in breast tumorigenesis. For details, please see the article by Martins and colleagues on page 503.

AACR American Association for Cancer Research

CANCER DISCOVERY

2 (6)

Cancer Discovery 2012;2:OF6-568.